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CASE REPORT
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Abstract: Diffuse iris melanoma is an uncommon variant of anterior uveal melanoma. It is 
characterized by heterochromia and unilateral glaucoma secondary to angle invasion, and can be 
difﬁ  cult to diagnose. We present a patient who had been managed for left-sided raised intraocular 
pressure with latanoprost eye drops for 12-months and pigmentary changes were subsequently 
noted. On referral to the Ocular Oncology Unit, Sydney, iris melanoma was suspected and 
conﬁ  rmed on iridectomy, and the eye was eventually enucleated.
Keywords: iris, diffuse melanoma, glaucoma, latanoprost, cytogenetics
Introduction
Iris melanoma is a rare tumor representing 2%–3% of all uveal melanoma, and the 
diffuse variant accounts for 10% of cases (Demirci et al 2002). It typically presents 
with darkening of the iris or blurred vision, and is characterized by unilateral glau-
coma and heterochromia. The tumor arises from malignant transformation of an iris 
stromal melanocyte, and spreads throughout the iris to invade the angle and extraocular 
tissues.
Case report
A 70-year old man was referred to the Sydney Ocular Oncology Unit for evaluation of 
refractory left sided glaucoma and iris heterochromia (Figure 1). 12-months previously 
he had presented elsewhere with raised left intraocular pressure, associated with asym-
metrical disc cupping, open angles on gonioscopy and some early left nasal changes 
on perimetry. The diagnosis of glaucoma was made and timolol and latanoprost eye 
drops were started. After 9-months of treatment pigmentary changes in the left iris 
were observed and thought to be related to latanoprost. On subsequent evaluation 
malignant heterochromia was suspected and he was referred to the Unit.
Ophthalmic examination revealed a visual acuity of 6/7.5 OD and 6/7.5 OS, right 
and left intra ocular pressure (IOP) of 10 and 18 mmHg, and a sluggish left pupillary 
reﬂ  ex. On slit-lamp examination there was ciliary injection and a diffuse pigmented iris 
lesion with irregular surface protrusions and loss of architectural integrity (Figure 1). 
The anterior chamber, lens and media were clear and left glaucomatous optic disc 
atrophy was seen. Gonioscopy showed angle invasion with outﬂ  ow obstruction between 
clock-hours 4 and 11.
Ultrasound biomicroscopy was performed, which conﬁ  rmed an irregular iris 
surface and demonstrated some thickening of segments of the iris root. CT head, chest, 
abdomen and pelvis showed no evidence of metastatic disease, and blood tests were 
normal. A left-temporal iridectomy through clear cornea was performed which revealed 
an iris melanoma. Because of diffuse angle involvement and refractory glaucoma, 
enucleation was performed and no extraocular extension was detected. Histopathology Clinical Ophthalmology 2007:1(3) 340
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demonstrated a diffuse iris melanoma with predominant 
epithelioid cell morphology (Figure 2). Fluorescence in situ 
hybridization on the parafﬁ  n-embedded specimen revealed 
a single pattern of loss of a chromosome 3 locus but no gain 
of chromosome 8.
Discussion
Diffuse iris melanoma can be challenging to diagnose, and a 
high degree of suspicion is necessary in patients presenting 
with pigmentary change and unilateral glaucoma. Patients 
can receive medical or surgical treatment for glaucoma before 
the tumor is detected (Demirci et al 2002).
In this case topical latanoprost obscured a malignant 
cause for heterochromia. Latanoprost has been compared to 
other commercially available prostaglandin analogues, and 
all cause a similar degree of iris pigmentary changes (Li 
et al 2006). With increasing use of topical prostaglandins, 
heterochromia and glaucoma are not uncommon (Alm and 
Stjernschantz 1995); however, ﬁ  ndings on slit-lamp were 
suggestive of malignancy. Concern about the oncogenic 
potential of topical prostaglandins has been raised previously; 
however, subsequent laboratory and clinical studies have not 
demonstrated any relationship of this kind (Dutkiewicz et al 
2000). In this case an etiological link between latanoprost and 
malignancy is unlikely given the brief interval between expo-
sure and clinical melanoma; however, benign melanosis is 
noted in the pigment epithelial layer of the iris (Figure 2).
The mechanisms responsible for glaucoma caused by iris 
melanoma were investigated by Shields et al in a series of 
169 patients. A diffuse conﬁ  guration, angle invasion with 
tumor seeds, peripherally based tumors and increasing tumor 
size predicted raised IOP (Shields, Materin et al 2001). In 
this case raised IOP was due to trabecular meshwork and 
angle invasion, which was associated with a poor visual 
prognosis. Although this is more commonly a feature of ring 
melanoma of the ciliary body (Demirci et al 2001), there was 
not enough contiguous ciliary body involvement to suggest 
a ring melanoma (Figure 2).
Raised IOP can be medically managed with beta 
blockers, alpha-2 agonists and carbonic anhydrase inhibi-
tors. Latanoprost, which upregulates matrix metalloprote-
ases (MMPs) and thereby reduces resistance to uveoscleral 
ﬂ  ow may theoretically increase the risk of extraocular 
dissemination of tumor cells through the same pathway. 
Given that MMPs are found in the sclera as well, latanoprost 
may affect scleral collagen and improve trans-scleral ﬂ  ow, 
however there is no evidence that cellular material can pass 
through this route. Drainage surgery, such as trabeculec-
tomy or shunt procedures, is deﬁ  nitely contraindicated 
as it may facilitate extraocular tumor spread, and such 
procedures are often responsible for cases of metastasis 
(Girkin et al 2002).
A large proportion of iris melanomas will not grow and 
lesions less than 3 mm can be treated conservatively with 
initial trial of observation (Conway et al 2001). Any sus-
picious lesion warrants histological diagnosis with either 
ﬁ  ne needle aspirate or iridectomy/iridocyclectomy. Under 
hypotensive general anesthesia, the latter involves a 90% 
thickness posteriorly-hinged scleral ﬂ  ap to 2–3 mm on either 
side of the tumor, followed by a large lamellar ﬂ  ap splitting 
the corneal stroma overlying the tumor and subsequent 
removal. These techniques minimize the risk of incomplete 
excision and dissemination of malignant cells (Char et al 
2001; Conway et al 2001). While local surgical removal is 
used to treat most iris melanomas, it is contraindicated in 
the presence of raised intraocular pressure due to extensive 
angle involvement by tumor cells. Enucleation is indicated 
for diffusely growing melanomas, widespread angle invasion 
Figure 1 Right and left eyes on presentation. (a) OD. Normal iris. (b) OS. There is an irregular pigmented lesion with loss of iris architecture associated with ciliary injection.
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and glaucoma (Demirci et al 2002). Plaque brachytherapy 
can be used to control diffuse variants, but long term data is 
lacking (Finger 2001).
The chromosomal alterations of iris melanoma are poorly 
characterized. A few studies have indicated that they are 
distinct from those found in choroidal melanoma (Sisley et al 
1998). However, monosomy in chromosome 3 is a marker 
of poor prognosis in posterior uveal melanoma, and may 
imply a similarly poor prognosis in iris melanoma (Prescher 
et al 1995). The cytogenetic proﬁ  le of this case is difﬁ  cult to 
interpret but may represent an aggressive tumor biology.
The 5-year metastatic rate of diffuse iris melanoma has 
been reported as 13% over 6-years (Demirci et al 2002), 
compared to 3% after 5-years for circumscribed iris mela-
noma (Shields CL, Shields JA et al 2001). Metastases are 
invariably hematogenous, with the majority going to the liver 
like other uveal melanomas (Millodot et al 2006). This man 
has been recommended biannual follow up with baseline full 
systemic examination, liver imaging and evaluation of blood 
count and liver function.
Conclusion
This case exemplifies a potential clinical problem of a 
prostaglandin analogue masking a malignant cause of hetero-
chromia. Establishing the correct diagnosis of iris melanoma 
is essential, particularly since various treatment modalities for 
primary glaucoma may contribute to tumor seeding. Tissue 
diagnosis is required in most cases and with appropriate surgi-
cal techniques no increased risk of spreading melanoma cells 
at biopsy has been demonstrated (Char et al 2001). Because 
diffuse iris melanoma is typically found with refractory raised 
intraocular pressure after invasion of the angle has occurred, 
enucleation is a relatively common end point.
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